全文获取类型
收费全文 | 365908篇 |
免费 | 43538篇 |
国内免费 | 13998篇 |
专业分类
耳鼻咽喉 | 3738篇 |
儿科学 | 6149篇 |
妇产科学 | 6901篇 |
基础医学 | 45100篇 |
口腔科学 | 7135篇 |
临床医学 | 29986篇 |
内科学 | 43369篇 |
皮肤病学 | 5578篇 |
神经病学 | 9831篇 |
特种医学 | 10417篇 |
外国民族医学 | 343篇 |
外科学 | 43625篇 |
综合类 | 52985篇 |
现状与发展 | 83篇 |
一般理论 | 3篇 |
预防医学 | 14244篇 |
眼科学 | 3572篇 |
药学 | 26841篇 |
172篇 | |
中国医学 | 10386篇 |
肿瘤学 | 102986篇 |
出版年
2024年 | 318篇 |
2023年 | 6415篇 |
2022年 | 8697篇 |
2021年 | 15738篇 |
2020年 | 15663篇 |
2019年 | 14406篇 |
2018年 | 14252篇 |
2017年 | 14952篇 |
2016年 | 15937篇 |
2015年 | 18195篇 |
2014年 | 26507篇 |
2013年 | 27416篇 |
2012年 | 22745篇 |
2011年 | 24044篇 |
2010年 | 18633篇 |
2009年 | 18608篇 |
2008年 | 19328篇 |
2007年 | 19069篇 |
2006年 | 17037篇 |
2005年 | 14887篇 |
2004年 | 12779篇 |
2003年 | 10838篇 |
2002年 | 8959篇 |
2001年 | 7943篇 |
2000年 | 6551篇 |
1999年 | 5580篇 |
1998年 | 4500篇 |
1997年 | 4175篇 |
1996年 | 3517篇 |
1995年 | 3626篇 |
1994年 | 3116篇 |
1993年 | 2541篇 |
1992年 | 2166篇 |
1991年 | 1975篇 |
1990年 | 1541篇 |
1989年 | 1410篇 |
1988年 | 1282篇 |
1987年 | 1061篇 |
1986年 | 932篇 |
1985年 | 1175篇 |
1984年 | 1030篇 |
1983年 | 712篇 |
1982年 | 735篇 |
1981年 | 623篇 |
1980年 | 535篇 |
1979年 | 391篇 |
1978年 | 267篇 |
1977年 | 211篇 |
1976年 | 162篇 |
1975年 | 87篇 |
排序方式: 共有10000条查询结果,搜索用时 171 毫秒
71.
Robert J. Motzer MD David F. McDermott MD Bernard Escudier MD Mauricio Burotto MD Toni K. Choueiri MD Hans J. Hammers MD PhD Philippe Barthélémy MD PhD Elizabeth R. Plimack MD Camillo Porta MD Saby George MD Thomas Powles MD Frede Donskov MD PhD Howard Gurney MD Christian K. Kollmannsberger MD Marc-Oliver Grimm MD Carlos Barrios MD Yoshihiko Tomita MD PhD Daniel Castellano MD Viktor Grünwald MD PhD Brian I. Rini MD M. Brent McHenry PhD Chung-Wei Lee MD PhD Jennifer McCarthy MA Flavia Ejzykowicz PhD Nizar M. Tannir MD 《Cancer》2022,128(11):2085-2097
72.
73.
《Diagnostic Histopathology》2022,28(12):522-533
Neoplasms of bone with numerous non-neoplastic osteoclast type giant cells are relatively common and exhibit diverse phenotypes of the neoplastic cells. These tumors have a broad spectrum of biological potential which necessitates accurate recognition and diagnosis. Their clinicopathological features are overlapping, therefore, immunohistochemistry and molecular studies may be required for evaluation. Correlation with imaging studies provides additional information that should be incorporated into the pathological interpretation. 相似文献
74.
Georgios D. Lianos MD PhD Maximos Frountzas MD MPA PhD Dimitrios Schizas MD PhD Evangelos G. Baltagiannis MD George A. Alexiou MD PhD Christina Bali MD PhD Georgios K. Glantzounis MD PhD Michail Mitsis MD PhD Konstantinos Vlachos MD PhD 《Journal of surgical oncology》2023,127(1):7-10
During first outburst of COVID-19, several strategies had been applied for surgical oncology patients to minimize COVID-19 transmission. COVID-19 infection seemed to compromise survival and major complication rates of surgical oncology patients. However, survival, tumor progression and recurrence rates of surgical oncology patients were associated to the consequences of COVID-19 pandemic on their management. In addition, the severity of COVID-19 infections has been downgraded. Therefore, management of surgical oncology patients should be reconsidered. 相似文献
75.
76.
目的 分析术前SCC、CYFRA21-1与肺鳞癌临床病理特征、预后之间的关系。方法 收集2017年3月~2018年4月在云南省肿瘤医院确诊的肺鳞癌患者100例为观察组,确诊为肺良性肿瘤患者90名为肺良性肿瘤组、以及正常人群90名为健康人群组。通过电化学发光法对SCC、CYFRA21-1两种指标进行检测。检测SCC、CYFRA21-1含量,分析在肺鳞癌中表达的临床意义。结果 SCC、CYFRA21-1在肺鳞癌中比在肺良性肿瘤、健康人群中含量要高,差异有统计学意义(P<0.001),并且敏感性均高于其他两组;男性患者的SCC、CYFRA21-1含量高于女性患者,差异具有统计学意义(P<0.05);SCC、CYFRA21-1含量在年龄≥60岁的含量高于<60岁患者,差异无统计学意义(P>0.05);有吸烟史患者的SCC含量高于无吸烟史患者,差异无统计学意义(P>0.05)。CYFRA21-1在吸烟史患者中高表达,差异有统计学意义(P<0.05);SCC、CYFRA21-1在有淋巴结转移、远处转移、肿瘤直径≥5 cm、病理分期为晚期时高表达,差异具有统计学意义(P<0.05);SCC、CYFRA21-1阳性患者OS、PFS比阴性患者短;SCC、CYFRA21-1两者之间呈正相关,相关系数(r)为0.630。结论 SCC、CYFRA21-1在肺鳞癌中表达上调;SCC、CYFRA21-1与性别之间存在某种内在联系;SCC、CYFRA21-1与肺鳞癌的TNM分期呈正相关;SCC、CYFRA21-1阳性患者OS、PFS比阴性患者短;SCC、CYFRA21-1两者之间呈正相关,相关系数(r)为0.630。 相似文献
77.
《Drug discovery today》2022,27(9):2551-2561
B cell lymphoma 2 (BCL2) overexpression in a range of human tumors is often related to chemotherapy resistance and poor prognosis. GC-rich regions upstream of the P1 promoter in human BCL2 can form G-quadruplex (G4) structures through the stacking of four Hoogsteen-paired guanine bases. Stabilizing the G4 fold implies the inhibition of BCL2 expression and, thus, small molecules that selectively bind to the G4 are promising anticancer candidates. In this review, we discuss the structural aspects, binding affinity, selectivity, and biological activity of well-characterized BCL2 G4 binding ligands in vitro and in vivo. We also explore future directions in the research and development of G4-based anticancer therapeutics. 相似文献
78.
《Transfusion and apheresis science》2022,61(1):103368
The endothelium is a single-layered structure that responds to physical and chemical signals with various factors it synthesizes. In the early days of its discovery, as the inner wall of the vessels, the endothelium was thought to be a simple barrier that lays on the surface. Over time it is discovered that endothelium maintains body homeostasis with the molecules it synthesizes, despite its simple single-layer structure. It has been accepted as an important organ that contributes to the maintenance of vascular tone, cell adhesion, inflammation, vascular permeability and coagulation. Any imbalance in these physiological and pathological events causes endothelial dysfunction. This can cause many diseases such as atherosclerosis, hypertension, diabetes, or it can occur because of these. Endothelial related disorders may also complicate hematopoietic stem cell transplantation (HSCT), which is used to treat various hematologic and neoplastic diseases. These life-threatening complications include graft-versus-host disease, hepatic veno-occlussive disease, transplant-associated thrombotic microangiopathy and diffuse alveolar hemorrhage. They share a similar pathophysiology involving endothelial cells with different clinical presentations. Therefore, current researche on the issue is putting the endothelium under the spotlight for novel markers and treatment options that should be used to monitor or treat at least some of these complications following HSCT. 相似文献
79.
《Cancer radiothérapie》2022,26(4):611-615
In order to provide more convenient irradiation regimens for patient comfort, radiation facility organization and health expenses, new hypofractionated protocols have been evaluated. Moderately (dose/fraction: 2.3 to 3 Gy), then ultra (dose/fraction: 5.2 to 6.1 Gy) hypofractionated irradiations were first validated. The current question is: is it possible to go forward using extreme hypofractionated regimens (EHR) based on 1 to 3 fractions. Different irradiation techniques are under investigation. However, brachytherapy remains the smartest way to deliver a high dose in a small volume. We report prospective and retrospective study results which evaluated EHR for breast and prostate brachytherapy. While oncological outcome and toxicity profile appear extremely encouraging for low-risk breast cancer after a 1 to 4 fractions (6.25 to 20 Gy/fraction), the use of a single fraction of 19 to 23 Gy appears debatable for prostate cancer. Brachytherapy represents an emblematic example of EHR but longer follow-up and more mature results are awaited in order to specify the right indications and refine the EQD2 calculation method including new biological and technical factors. 相似文献
80.